Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Vera Therapeutics

Vera Therapeutics (NASDAQ: VERA) insider transactions

In the twelve months to 10 November 2026, executives and directors of Vera Therapeutics reported 25 open-market sales of 225,555 shares ($9.0m) and 1 open-market purchase of 5,882 shares ($249,985), by 9 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Vera Therapeutics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
15 September 2026Fordyce MarshallPresident and CEOOption exercise, 10b5-1 plan+18,500$2.90253,744Form 4
15 September 2026Fordyce MarshallPresident and CEOOpen-market sale, 10b5-1 plan−18,500$37.00235,244Form 4
11 September 2026Young Joseph RSVP, Finance, Chief Acct OffcrOption exercise+5,000$3.9480,754Form 4
2 September 2026Fordyce MarshallPresident and CEOOption exercise, 10b5-1 plan+18,500$2.90253,744Form 4
2 September 2026Fordyce MarshallPresident and CEOOpen-market sale, 10b5-1 plan−18,500$35.12235,244Form 4
3 August 2026Boman Nancy LeeChief Regulatory OfficerGrant or award+44,987—44,987Form 4
7 July 2026Fordyce MarshallPresident and CEOOpen-market sale, 10b5-1 plan−1,000$40.78197,244Form 4
7 July 2026Fordyce MarshallPresident and CEOOpen-market sale, 10b5-1 plan−32,550$42.07164,694Form 4
7 July 2026Fordyce MarshallPresident and CEOOpen-market sale, 10b5-1 plan−10,500$42.86154,194Form 4
7 July 2026Fordyce MarshallPresident and CEOOpen-market sale, 10b5-1 plan−2,200$43.59151,994Form 4
23 June 2026Fordyce MarshallPresident and CEOOpen-market sale, 10b5-1 plan−18,412$37.93198,332Form 4
23 June 2026Fordyce MarshallPresident and CEOOpen-market sale, 10b5-1 plan−88$38.43198,244Form 4
12 May 2026Fordyce MarshallPresident and CEOOpen-market sale, 10b5-1 plan−14,219$36.64221,025Form 4
12 May 2026Fordyce MarshallPresident and CEOOpen-market sale, 10b5-1 plan−4,281$37.09216,744Form 4
14 April 2026Fordyce MarshallPresident and CEOOpen-market sale, 10b5-1 plan−14,130$43.66244,065Form 4
14 April 2026Fordyce MarshallPresident and CEOOpen-market sale, 10b5-1 plan−7,921$44.58236,144Form 4
14 April 2026Fordyce MarshallPresident and CEOOpen-market sale, 10b5-1 plan−900$45.51235,244Form 4
23 March 2026Wright-Mitchell JaneChief Legal OfficerGrant or award+42,403—42,403Form 4
13 March 2026Young Joseph RSVP, Finance, Chief Acct OffcrOption exercise+10,000$3.9475,754Form 4
23 February 2026Johnson David LeeChief Operating OfficerOpen-market sale−2,579$41.9845,727Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Vera Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.